Nasdaq:VYGR

<!-- Name:DistributionId Value:8841596 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into an employment agreement with a…

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today…

Novel passive antibodies bind to paired helical filamentous tau and inhibit propagation of pathological tau Vectorized antibody demonstrates durable CNS expression more than six months post-dose Research presented at the Alzheimer’s…

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, will…

VCAP-102 capsid achieved respective 60-fold and 50-fold improvements in brain transduction in non-human primates and mice compared to conventional AAV9 capsids with IV dosing Data demonstrate potential of multiple TRACER capsids to target…

Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatability and CNS tropisms of novel TRACER™ AAV9- and AAV5-derived capsids Preclinical data to be…

CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced nine data…

Novel intravenous (IV) vectorized antibody approach designed to activate innate immune system, destroy metastatic breast cancer tumors, and inhibit tumor progression in CNS Proprietary TRACER™ capsid screening technology enables broad…

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today…